PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY APPLICATION Market segmentation by application Comparison by application Autoimmune disorders - Market size and forecast 2018-2023 Oncology - Market size and forecast 2018-2023 Market opportunity by application PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increasing research grants Special drug designations Rising number of strategic alliances PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Astellas Pharma Inc. Eli Lilly and Co. Incyte Corp. Novartis AG Pfizer Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Application - Market share 2018-2023 (%) Exhibit 19: Comparison by application Exhibit 20: Autoimmune disorders - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Pipeline of JAK inhibitors for autoimmune disorders Exhibit 22: Autoimmune disorders - Year-over-year growth 2019-2023 (%) Exhibit 23: Oncology - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Pipeline of JAK inhibitors for oncology Exhibit 25: Oncology - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by application Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Astellas Pharma Inc. - Vendor overview Exhibit 51: Astellas Pharma Inc. - Business segments Exhibit 52: Astellas Pharma Inc. - Organizational developments Exhibit 53: Astellas Pharma Inc. - Geographic focus Exhibit 54: Astellas Pharma Inc. - Key offerings Exhibit 55: Astellas Pharma Inc. - Key customers Exhibit 56: Eli Lilly and Co. - Vendor overview Exhibit 57: Eli Lilly and Co. - Business segments Exhibit 58: Eli Lilly and Co. - Organizational developments Exhibit 59: Eli Lilly and Co. - Geographic focus Exhibit 60: Eli Lilly and Co. - Segment focus Exhibit 61: Eli Lilly and Co. - Key offerings Exhibit 62: Eli Lilly and Co. - Key customers Exhibit 63: Incyte Corp. - Vendor overview Exhibit 64: Incyte Corp. - Business segments Exhibit 65: Incyte Corp. - Organizational developments Exhibit 66: Incyte Corp. - Geographic focus Exhibit 67: Incyte Corp. - Key offerings Exhibit 68: Incyte Corp. - Key customers Exhibit 69: Novartis AG - Vendor overview Exhibit 70: Novartis AG - Business segments Exhibit 71: Novartis AG - Organizational developments Exhibit 72: Novartis AG - Geographic focus Exhibit 73: Novartis AG - Segment focus Exhibit 74: Novartis AG - Key offerings Exhibit 75: Novartis AG - Key customers Exhibit 76: Pfizer Inc. - Vendor overview Exhibit 77: Pfizer Inc. - Business segments Exhibit 78: Pfizer Inc. - Organizational developments Exhibit 79: Pfizer Inc. - Geographic focus Exhibit 80: Pfizer Inc. - Segment focus Exhibit 81: Pfizer Inc. - Key offerings Exhibit 82: Pfizer Inc. - Key customers Exhibit 83: Validation techniques employed for market sizing Exhibit 84: Definition of market positioning of vendors    

Astellas Pharma Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, and Pfizer Inc.